Skip to main content

Table 7 Quality of life score according to the Treatment modalities and Radiation method used in the CC patients

From: Quality of life among cervical cancer patients following completion of chemoradiotherapy at Ocean Road Cancer Institute (ORCI) in Tanzania

QLQ Items

Treatment

P#

Radiation Mode

P*

R

C

S + C + R

E

E + B

n = 19

n = 298

n = 6

n = 28

n = 295

QLQ-C30 Functional scales

Global Health Status/QOL

71.5 ± 17.9

63.7 ± 17.5

79.2 ± 12.6

0.018

59.2 ± 21.9

64.9 ± 17.1

0.136

Physical Functioning

90.9 ± 10.5

85.4 ± 14.8

85.6 ± 14.9

0.340

75.7 ± 17.5

86.7 ± 13.9

0.001

Role Functioning

93.0 ± 14

89.9 ± 18.6

91.7 ± 20.4

0.726

76.2 ± 26.6

91.5 ± 16.9

0.001

Emotional Functioning

83.8 ± 24.4

80.1 ± 22.6

77.8 ± 25.6

0.524

63.4 ± 27.5

81.9 ± 21.6

0.000

Cognitive Functioning

87.7 ± 22.8

81.1 ± 24.1

77.8 ± 20.2

0.322

64.3 ± 32.9

83.1 ± 22.3

0.003

Social Functioning

78.9 ± 31.3

74.8 ± 30.5

91.7 ± 20.4

0.300

55.4 ± 38.5

77.2 ± 28.8

0.002

QLQ-C30 Symptom scales

Fatigue

16.4 ± 16.7

16.3 ± 19.1

7.4 ± 9.1

0.581

28.6 ± 23.5

15 ± 17.9

0.001

Nausea & Vomiting

3.5 ± 8.9

5.3 ± 15.6

2.8 ± 6.8

0.999

11.9 ± 26.8

4.5 ± 13.4

0.094

Pain

19.3 ± 19.5

19.6 ± 22.9

30.6 ± 32.3

0.664

29.2 ± 24.7

18.9 ± 22.5

0.018

Dyspnea

1.8 ± 7.6

4.1 ± 14.5

5.6 ± 13.6

0.693

6 ± 15.9

3.8 ± 14.1

0.310

Insomnia

21.1 ± 31.8

12.1 ± 24.2

27.8 ± 44.3

0.270

26.2 ± 34.4

11.6 ± 23.9

0.004

Appetite Loss

12.3 ± 19.9

8.9 ± 21.9

0

0.215

25 ± 33.5

7.4 ± 19.5

0.000

Constipation

15.8 ± 28

19.2 ± 27.5

16.7 ± 27.9

0.716

40.5 ± 38.9

16.9 ± 25.3

0.001

Diarrhea

3.5 ± 15.3

3.9 ± 16.1

0

0.770

3.6 ± 13.9

3.8 ± 16

0.948

Financial difficulties

64.9 ± 42.3

63.6 ± 36.2

61.1 ± 44.3

0.868

82.1 ± 32.1

61.9 ± 36.6

0.001

QLQ-CX24 Symptom scales

Symptom Experience

10.7 ± 9.4

14.4 ± 11.6

10.1 ± 6.5

0.315

21.4 ± 17.5

13.4 ± 10.5

0.029

Body Image

15.8 ± 19.4

20.0 ± 27.0

14.8 ± 18.1

0.984

35.8 ± 32.5

18.1 ± 25.3

0.004

Sexual/Vaginal Functioning

58.3 ± 28.9

28.5 ± 21.3

20.8 ± 17.7

0.153

37.5 ± 17.7

29.3 ± 22.2

0.479

Lymphoedema

8.8 ± 24.4

7.6 ± 17.2

11.1 ± 17.2

0.688

21 ± 26.4

6.6 ± 16.1

0.000

Peripheral Neuropathy

21.1 ± 22.8

22.7 ± 29.2

33.3 ± 29.8

0.556

34.6 ± 32.7

21.7 ± 28.3

0.027

Menopausal Symptoms

19.3 ± 30.1

16.6 ± 29.9

44.4 ± 45.5

0.083

24.7 ± 32.8

16.6 ± 30.1

0.092

Sexual Worry

42.1 ± 48.2

45.5 ± 43.3

61.1 ± 49.1

0.666

78.6 ± 38.7

42.4 ± 42.8

0.000

QLQ-CX24 Functional scales

Sexual Activity

8.8 ± 21.8

9 ± 18.7

16.7 ± 27.9

0.654

2.4 ± 8.7

9.8 ± 19.6

0.048

Sexual Enjoyment

44.4 ± 50.9

43.1 ± 29.9

66.7 ± 0

0.491

16.7 ± 23.6

44.6 ± 30.3

0.186

  1. R  radiotherapy, C  chemoradiotherapy, S + C + R  surgery with adjuvant chemo-radiotherapy, E  external beam radiotherapy, E + B  combined external beam radiotherapy and brachytherapy. Values are in mean score ± SD. Significance P < 0.005 by Kruskal Wallis test# or Mann Whitney U test* as appropriate and significant values are bolded
Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us